Skip to content
value.today

C2i Genomics, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2019
Total raised
$12 M
1 round on record
Latest round
$12 M
May 2020
First round on record
May 2020
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of C2i Genomics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$12 MNo. 1$10 to $50 million

C2i Genomics, Inc.: Raise no. 1, May 2020

Investors in this round

8 investors had bought by the notice of Jun 8, 2020: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
$70,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$450,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Asaf Zviran · Executive Officer, Director
  • Ezra Sofer · Executive Officer, Director
  • Eli Casdin · Director
  • Omri Amirav-Drori · Director
  • Shaun Rodriguez · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ezra Sofer, GM and CFO. Source: SEC Form D, newest notice filed Jun 8, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • C2i Genomics, Inc. had no revenue when it filed its newest notice of a funding round (Jun 2020).

    SEC Form D (revenue range) · Jun 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of C2i Genomics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by C2i Genomics, Inc.
NameRoleNamed in
Asaf ZviranExecutive officerJun 2020
Ezra SoferExecutive officerJun 2020
Asaf ZviranDirectorJun 2020
Eli CasdinDirectorJun 2020
Ezra SoferDirectorJun 2020
Omri Amirav-DroriDirectorJun 2020
Shaun RodriguezDirectorJun 2020